Amlodipine/celecoxib
Combination of | |
---|---|
Amlodipine | Calcium channel blocker |
Celecoxib | Nonsteroidal anti-inflammatory drug (NSAID) |
Clinical data | |
Trade names | Consensi |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Amlodipine/celecoxib, sold under the brand name Consensi, is a fixed-dose combination medication used to treat both hypertension and osteoarthritis at the same time in adults.[1][2] It contains amlodipine, as the besilate, and celecoxib.[1] It is taken by mouth.[1]
The most common side effects include edema, abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and rash.[1]
It was approved for medical use in the United States in May 2018.[3]
Medical uses
[edit]Amlodipine/celecoxib is indicated for use in adults for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate.[1]
History
[edit]Amlodipine/celecoxib was approved for use in the United States in May 2018.[3]
References
[edit]- ^ a b c d e f "Consensi- amlodipine besylate and celecoxib tablet". DailyMed. 17 December 2019. Retrieved 14 May 2020.
- ^ Smith SM, Cooper-DeHoff RM (February 2019). "Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis". The American Journal of Medicine. 132 (2): 172–174. doi:10.1016/j.amjmed.2018.08.027. PMID 30240679. S2CID 52312672.
- ^ a b "Drug Approval Package: Consensi (amlodipine and celecoxib)". U.S. Food and Drug Administration (FDA). 29 November 2018. Retrieved 14 May 2020.